The Life-Saving Impact of Early Diagnosis and Treatment for Spinal Muscular Atrophy Type 1
DOI:
https://doi.org/10.36283/ziun-pjmd14-2/073Keywords:
Spinal Muscular Atrophy (SMA), Werdnig-Hoffmann Disease, Motor Neuron Disease, Muscle Weakness, Hypotonia, Respiratory Insufficiency, Electromyography (EMG), Infantile Spinal Muscular Atrophy, Creatine Kinase (CK-MB).Abstract
Spinal muscular atrophy (SMA) is a hereditary neuromuscular condition caused by mutations in the Survival Motor Neuron 1 gene. This report presents a clinical description of a case diagnosed with SMA and highlights the significance of early recognition and multidisciplinary management. SMA affects the anterior horn cells in the spinal cord, leading to progressive muscle weakness and atrophy. It is classified into four types based on the age of onset and clinical severity. Type 1 SMA, also known as Werdnig-Hoffmann disease, is the most severe form and generally manifests within the first six months of life. A boy was suspected of having SMA type 1 due to his hypotonic posture and 2.8 kg birth weight. Symptomatic treatment and diagnostic tests like MRI were done, but the infant died after a few days of readmission on day 28 due to severe breathing issues and muscular atrophy. The diagnosis was confirmed after his death.
References
Rizvi SB, Ahmed H, Zaman A, Ali AM, Shah HH, Rauf SA, Dave T. Spinal muscular atrophy type 1: A fatal case in a 1‐year‐old girl with delayed diagnosis. Clinical Case Reports. 2024 Feb;12(2):e8513. https://doi.org/10.1002/ccr3.8513
Aysu B, Yılmaz S, Aral N, Aydoğdu F. Challenges Faced By Families of SMA Patients. Ebelik ve Sağlık Bilimleri Dergisi. 2024 Oct 9;7(3):541-7.https://doi.org/10.62425/esbder.1497446.
Khuntha S, Prawjaeng J, Ponragdee K, Sanmaneechai O, Srinonprasert V, Leelahavarong P. Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis. Appl Health Econ Health Policy. 2025 Mar;23(2):277-290. doi: 10.1007/s40258-024-00915-y. Epub 2024 Sep 27. PMID: 39333302; PMCID: PMC11811457.
Weng W, Shieh J, Huang H, Tsai L. 153P Long-term effectiveness of risdiplam in non-ambulant SMA patients with prolonged disease duration. Neuromuscular Disorders. 2024 Oct 1;43:104441-588.https://doi.org/10.1016/j.nmd.2024.07.597
Cetik RM, Ovadia D, Mladenov K, Kruyt MC, Helenius I, Ahonen M, Studer D, Yazici M. Safety and efficacy of growth-friendly instrumentation for early-onset scoliosis in patients with spinal muscular atrophy type 1 in the disease-modifying treatment era. J Child Orthop. 2023 Nov 27;18(1):26-32. doi: 10.1177/18632521231214780. PMID: 38348442; PMCID: PMC10859117.
Stringer BW, Zhang Y, Taghipour-Sheshdeh A, Goh S, Kölbel H, Farrar MA, Wirth B, Giacomotto J. Clinical relevance of zebrafish for gene variants testing. Proof-of-principle with SMN1/SMA. bioRxiv. 2025 Jan 31:2025-01. doi: 10.1101/2025.01.30.632288v1
Schroth M, Deans J, Arya K, Castro D, De Vivo DC, Gibbons MA, Ionita C, Kuntz NL, Lakhotia A, Neil Knierbein E, Scoto M, Sejersen T, Servais L, Tian C, Waldrop MA, Vázquez-Costa JF. Spinal Muscular Atrophy Update in Best Practices: Recommendations for Diagnosis Considerations. Neurol Clin Pract. 2024 Aug;14(4):e200310. doi: 10.1212/CPJ.0000000000200310. Epub 2024 May 24. Erratum in: Neurol Clin Pract. 2025 Feb;15(1):e200386. doi: 10.1212/CPJ.0000000000200386. PMID: 38915908; PMCID: PMC11195435.
Bagga P, Singh S, Ram G, Kapil S, Singh A. Diving into progress: a review on current therapeutic advancements in spinal muscular atrophy. Front Neurol. 2024 May 24;15:1368658. doi: 10.3389/fneur.2024.1368658. PMID: 38854961; PMCID: PMC11157111.
Armengol VD, Darras BT, Abulaban AA, Alshehri A, Barisic N, Ben-Omran T, Bernert G, Castiglioni C, Chien YH, Farrar MA, Kandawasvika G, Khadilkar S, Mah J, Marini-Bettolo C, Osredkar D, Pfeffer G, Piazzon FB, Pitarch Castellano I, Quijano-Roy S, Saito K, Shin JH, Vázquez-Costa JF, Walter MC, Wanigasinghe J, Xiong H, Griggs RC, Roy B. Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability. Neurol Clin Pract. 2024 Feb;14(1):e200224. doi: 10.1212/CPJ.0000000000200224. Epub 2023 Dec 15. PMID: 38107546; PMCID: PMC10723640.
Yasar NE, Ozdemir G, Uzun Ata E, Ayvali MO, Ata N, Ulgu M, Dumlupınar E, Birinci S, Bingol I, Bekmez S. Nusinersen therapy changed the natural course of spinal muscular atrophy type 1: What about spine and hip? J Child Orthop. 2024 Mar 8;18(3):322-330. doi: 10.1177/18632521241235028. PMID: 38831860; PMCID: PMC11144372.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
